Clearmind Medicine (CMND) said Thursday that it has started a phase 1/2a clinical trial of CMND-100 in patients will alcohol use disorder at the Johns Hopkins University School of Medicine, the company's first clinical site in the US.
The biotechnology company said the trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100 and will also include preliminary efficacy evaluations to assess its potential in reducing alcohol cravings and consumption.
Price: 0.95, Change: -0.03, Percent Change: -3.06
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.